Navigation Links
Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory
Date:7/15/2008

SAN DIEGO, July 15 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that E.J. Brandreth has joined the company as Vice President of Quality and Regulatory. In this role, Mr. Brandreth will be responsible for leading Althea's quality and compliance programs, while overseeing the regulatory support activities, which are required to facilitate the launch of commercial manufacturing services.

(Photo: http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

"We are very excited to welcome E.J. Brandreth to Althea. The diverse experience he brings to the company is particularly valuable, as it spans everything from clinical development of innovative products, to the preparation and validation required for commercial launch of successful biopharmaceuticals. His background in clinical and commercial biological products is a perfect fit for the expanding scope of projects at Althea," stated Dr. Magda Marquet, President and Co-CEO of Althea Technologies.

Mr. Brandreth brings over fifteen years of experience in the regulatory and quality assurance fields for the biotechnology and pharmaceutical industries. Prior to joining Althea Technologies, he was Vice President of Quality at Favrille, Inc., where he had oversight of Quality Control, Quality Assurance, Validation and Metrology. In the course of his career he has managed the validation of 11 different biotechnology facilities, and led the Process Validation Programs for five CBER/EMEA product launches. Previous to Favrille, Mr. Brandreth was Senior Director of QA at BioMarin Pharmaceuticals, Inc. where he supported a variety of clinical products and launched two commercial products. Prior to that, he held management positions in QA, Validation and Regulatory Affairs at IDEC Pharmaceuticals, where he assisted in the development and launch of Zevalin(R) and Rituxan(R), CBER's first approved monoclonal antibody for cancer. Additionally, Mr. Brandreth has helped to develop two Parenteral Drug Association (PDA) technical reports.

E.J. Brandreth added, "I am very pleased to join the outstanding team of professionals here at Althea Technologies. I've watched the company's growth and I am really happy that I can call upon my experience to help assure the quality, compliance and facility validation efforts underway, which will best serve Althea's clients. I'm joining Althea as the activities focused upon the release of the newly constructed state-of-the-art commercial-scale facility head into high gear, so I will be able to jump right in as we write this exciting new chapter in the company's history."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling. For more information, visit http://www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... home care professionals, today announced that it has raised $1.675 M in seed ... , Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s ...
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... August 17, 2017 , ... Navigating ... a Florida-based oncology business advisor to oncology practices, announced today the results of ... of attributable savings from resolving critical clinical issues that would have otherwise resulted ...
(Date:8/16/2017)... , ... August 16, 2017 , ... An August 3rd article on Reuters ... subject of a report in JAMA (the Journal of the American Medical Association). The study ... able to achieve BMIs under 30, when compared to patients with lower BMIs. At present, ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology: